ACAlexandra Canori

Alexandra Canori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexandra Canori has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Arianna Fiorentino

    Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai , New York, NY 10029

    2 shared publications
  • Blake Gurfein

    Fareon, Inc. , San Francisco, CA 94107

    2 shared publications
  • Christopher Santiago

    Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai , New York, NY 10029

    2 shared publications
  • David Maltz

    Fareon, Inc. , San Francisco, CA 94107

    2 shared publications
  • David Putrino

    Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai , New York, NY 10029

    2 shared publications
  • Devanshi Patel

    Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai , New York, NY 10029

    2 shared publications

Latest Publications

  • Open Access

    Microtesla magnetic therapy for cognitive impairment in long COVID: a randomized pilot study

    by Alexandra Canori, Eric Watson, Devanshi Patel, Arianna Fiorentino, Christopher Santiago, David Maltz, Blake Gurfein, David Putrino, Jacqueline Becker

    Cognitive impairment is common in post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection (long COVID) and substantially affects function and quality of life. Evidence suggests that sustained neuroinflammation, cerebrovascular dysfunction and mitochondrial impairment contribute to cognitive symptoms. Microtesla Magnetic Therapy (MMT) is a transcranial, low-amplitude radiofrequency magnetic field intervention that has shown anti-inflammatory and neuroprotective effects in preclinical models, suggesting potential value in long COVID and other neurological disorders. This is the first randomized controlled trial of MMT for long COVID cognitive impairment. We evaluated the feasibility (primary) and safety (secondary) of at-home MMT in individuals with objective cognitive impairment from long COVID. Thirty participants were randomized 2:1 to active or sham MMT and self-administered 15-min treatments at home twice weekly for 4 weeks, with remote monitoring, using a head-worn device delivering a non-thermal radiofrequency magnetic field to the whole brain. Feasibility was defined as completing at least 80% of prescribed treatments and all study visits. Safety was assessed by adverse events. Cognitive function and self-reported mood and quality of life were exploratory outcomes assessed at baseline, Week 4 (post-treatment) and Week 8 (follow-up). Feasibility was high: all participants who completed the study adhered to 100% of treatments, and usability ratings were strong. No device-related adverse events occurred. Compared with sham, active MMT participants showed significantly greater improvement from baseline to Week 8 in Wechsler Adult Intelligence Scale Digit Span Sequencing (P = 0.026), Hopkins Verbal Learning Test–Revised Total Recall (P = 0.044) and Delis-Kaplan Executive Function System Color Naming (P = 0.049). Other measures of attention, processing speed and executive function did not differ significantly between groups. Emotional well-being on the 36-Item Short Form Survey improved significantly more with active MMT at Week 8 (P = 0.017). Depression and anxiety decreased in both groups; the anxiety reduction was greater with active treatment in the linear mixed-effects model (week × treatment interaction, P = 0.038) but not in the between-group change score comparison (P = 0.057). At-home MMT was feasible, safe and well tolerated in individuals with cognitive impairment from long COVID. These preliminary, exploratory findings showed nominally significant between-group differences favouring active treatment on selected cognitive measures and emotional well-being and require confirmation in larger, adequately powered trials.

  • Open Access

    Plasma Proteomics Identifies a Microtesla Magnetic Therapy Response Signature in Long COVID

    by Nathan R. Brady, Alexandra Canori, David Maltz, Douglas Y. Kirsher, Wenyu Zhou, Jacqueline Becker, David F. Putrino, Blake T. Gurfein

    Cognitive impairment is a disabling feature of Long COVID with no established disease-modifying therapy, and little is known about the biological changes accompanying clinical improvement. Microtesla Magnetic Therapy (MMT) is a low amplitude radiofrequency electromagnetic field intervention delivered to the whole brain. In a randomized, sham-controlled feasibility trial, at home MMT was feasible, safe, and well tolerated, with evidence of clinical improvement among treated participants. We explored molecular changes associated with response using SomaScan 11K plasma proteomics on paired baseline and week 4 samples. Participants were classified post hoc within each treatment arm using a clinician-selected response phenotype integrating cognitive and symptom domains. These groups were used for proteomic, pathway, and OrganAge analyses. MMT response was associated with selective proteome remodeling and an exploratory 17 protein response pattern in which Hedgehog interacting protein (HHIP), a Hedgehog signaling antagonist, was most strongly associated with response. Directional pathway analysis identified patterns consistent with lower inflammatory and injury biology and higher repair and adaptive remodeling. OrganAge analysis showed trends toward lower Brain and Organismal OrganAge with MMT. These findings prioritize HHIP and the exploratory 17 protein response pattern for prospective validation and support evaluation of plasma proteomics for monitoring treatment response.

  • Open Access

    Microtesla Magnetic Therapy for cognitive impairment in post-acute sequelae of SARS CoV-2: A randomized controlled feasibility study

    by Alexandra Canori, Eric Watson, Devanshi Patel, Arianna Fiorentino, Christopher Santiago, David Maltz, Blake Gurfein, David Putrino, Jacqueline Becker

    Background: Cognitive impairment has significant implications for function and quality of life and is common in individuals with post-acute sequelae of SARS CoV-2, also known as long COVID (LC). Emerging evidence suggests that sustained neuroinflammation, cerebrovascular dysfunction, and mitochondrial impairment are contributors to cognitive symptoms. Microtesla Magnetic Therapy (MMT) is a low-amplitude radiofrequency magnetic field intervention that has demonstrated anti-inflammatory and neuroprotective effects in preclinical models, suggesting it may be valuable in the management of cognitive impairment from LC and other neurological disorders. This study is the first randomized controlled trial to evaluate MMT for LC-related cognitive impairment. Objective: To evaluate the feasibility, safety, and preliminary efficacy of an at-home MMT intervention in individuals with moderate-to-severe cognitive impairment from LC. Methods: In this prospective feasibility study, 30 participants with LC-related cognitive impairment were randomized (2:1) to receive active or sham MMT. Participants self-administered 15-minute treatments at home with remote monitoring twice weekly for 4 weeks using a head-worn device that delivered a nonthermal radiofrequency magnetic field to the whole brain. Feasibility was defined as completion of at least 80% of prescribed treatments and all study visits. Secondary outcomes included safety, cognitive function, and self-reported mood and quality of life assessed at baseline, post-treatment (Week 4), and follow-up (Week 8). Results: Feasibility was high, with 100% treatment adherence among participants who completed the study and strong usability ratings for at-home administration. There were no device-related adverse events. Compared with sham, participants receiving active MMT showed significantly greater improvements from baseline to Week 8 in WAIS-IV Digit Span Sequencing (p= 0.026), HVLT-R Recall (p= 0.044), and D-KEFS Color Naming (p= 0.049). Additional measures of attention, processing speed, and executive function demonstrated favorable trends in the active group. Emotional well-being, assessed by the SF-36, improved significantly in the active group at Week 8 compared with sham (p= 0.017), and mood symptoms showed clinically meaningful improvement. Conclusions: Administration of the MMT intervention at home was feasible, safe, and well tolerated in individuals with cognitive impairment from LC. Preliminary findings suggest sustained clinically meaningful improvements in multiple cognitive domains and mood following treatment.


  • Open Access

    Potential of social engagement for overcoming barriers to physical activity in individuals with spinal cord injury

    by Alexandra Canori, Rithika Lakshminarayanan, Melissa Nunn, Mary Schmidt-Read, Stephen S Intille, Shivayogi V Hiremath

    Introduction: Many barriers to physical activity (PA) exist for individuals with spinal cord injury (SCI). Social engagement may improve motivation to perform PA, which in turn may increase PA levels. This pilot study investigates how social engagement facilitated by mobile technology may reduce lack of motivation as a barrier to PA in individuals with SCI and demonstrates design implications for future technologies. Methods: A user-needs survey was conducted with participants in the community. We recruited 26 participants (16 individuals with SCI and 10 family members or peers). A participatory design process using semi-structured interviews was used to identify themes relating to PA barriers. Results: One theme related to PA barriers was lack of PA-focused forums to connect with peers. Participants with SCI considered connecting with other individuals with SCI more motivating than connecting with their family members. Another key finding was that participants with SCI did not perceive that personal fitness trackers were targeted towards wheelchair-based activities. Conclusions: Engagement and communication with peers who have similar functional mobility levels and life experiences can potentially improve motivation for PA; however, PA-motivational platforms are not tailored towards wheelchair-users. Our preliminary findings show that some individuals with SCI are not satisfied with current mobile-technologies for wheelchair-based PA.


  • Engaging Social Connections to Promote Physical Activity in Individuals with Spinal Cord Injury

    by Alexandra Canori, Rithika Lakshminarayanan, Aditya Ponnada, Stephen Intille, Shivayogi Hiremath